CNBC's Meg Tirrell reports the latest on the FDA putting Juno's cancer clinical trial on hold. The "Fast Money" traders weigh in on the biotech sector. » Read More
In a world of disappearing market returns and negative interest rates, the search for growth has become increasingly difficult, Goldman Sachs says.
U.S. Stocks closed higher Wednesday as Wall Street celebrated better-than-expected earnings off of a record week of gains for the Dow.
The Credit Suisse research team presented its highest-conviction stock ideas in a note to clients Friday.
Check out the companies making headlines after the bell Thursday: Juno Therapeutics, GAP, BioMarin Pharmaceutical and more.
U.S. cancer drug company Medivation is discussing opening its books to Sanofi, people familiar with the matter said on Tuesday.
Biotech stocks rallied after a government report said that Medicare cost-cutting measures will not be triggered this year.
Jim Cramer provides his opinion on caller stocks in the Lightning Round, and opines on one of his top energy plays.
The biopharmaceutical company authorized a repurchase of up to an additional $3 billion to its shareholders.
Twitter, Celgene and Best Buy are making headlines this Wednesday morning.
Take a look at some of Wednesday's early movers: TWTR, CSCO, PG, CELG, ANF, X, BBY & more
Yana Barton, Eaton Vance Management Portfolio Manager, and Stephen DeNichilo, Federated Kaufmann Funds Portfolio Manager, discuss some of the best plays in the small-cap and large-cap spaces.
The "Fast Money" traders weighed election risks for biotech after Obama officially endorsed Hillary Clinton.
The "Fast Money" traders give you 4 trades in biotech leading up to this year's controversial election.
Jim Cramer provides his opinion on caller-favorite stocks, but says this one's got a big problem with trust.
U.S. stocks closed mixed in below average trade volume Monday, with gains in health care offsetting declines in materials and energy as oil fell.
Three pillars of valuation driving biotech with CNBC's Meg Tirrell while the Fast Money panel discuss biotech as their top trade of the day.
The "Fast Money" traders get into biotech and give you 5 trades in a mixed sector.
Instead, a better — but less catchy — mantra may be "stay in May and sell in June."
Jim Cramer sees signs everywhere that the worst is over for pharma.
Options trader Dan Nathan says the biotech sector could get a boost on earnings.